NASDAQ · GLUE
Monte Rosa Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GLUE: Nov 5, 2026
Monte Rosa Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.33.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $0.10 | $-0.45 | 4 |
| Dec 2026 | $-0.16 | $0.38 | $-0.48 | 4 |
| Mar 2027 | $-0.37 | $0.02 | $-0.52 | 4 |
| Jun 2027 | $-0.39 | $0.05 | $-0.56 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · Fintel- Zacks · Oct 29, 9:00 AM EDTMonte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseMonte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 28, 8:21 AM EDTMonte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock Up(RTTNews) – Monte Rosa Therapeutics, Inc. (GLUE) announced that Novartis has initiated a second Phase 2 clinical study of MRT-6160 (DDY391), its investigational VAV1-directed molecular glue degrader, in participants with active moderate to severe psoriatic arthritis.
- Zacks · Oct 23, 6:51 AM EDTAre Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?Investors need to pay close attention to GLUE stock based on the movements in the options market lately.
- MarketBeat · Oct 6, 3:02 AM EDTMonte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study3 High-Risk Stocks That Soared in 2025 But Can Still Fly HigherMonte Rosa Therapeutics (NASDAQ:GLUE) reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-
- RTTNews · Oct 1, 12:59 PM EDTMonte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1(RTTNews) – Thursday, Monte Rosa Therapeutics, Inc. (GLUE) announced positive results from the Phase 1 GFORCE-1 study of MRT-8102 in obese subjects with elevated cardiovascular disease (CVD) risk.
- RTTNews · Oct 1, 12:36 PM EDTMRT-8102 Delivers Broad Inflammation Reductions In Monte Rosa Trial(RTTNews) – Thursday, Monte Rosa Therapeutics (GLUE) reported positive Phase 1 results for MRT-8102, showing broad reductions in inflammatory and cardiovascular disease-related biomarkers in obese subjects with elevated cardiovascular risk.
- Fintel · Oct 1, 6:36 AM EDTHC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy ratingFintel reports that on October 1, 2026, HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics (NASDAQGS:GLUE) with a Buy recommendation.Prior to this rating action, the stock's pre-action close was $11.93 on September 30, 2026. This close represents a one-week pri
- RTTNews · Oct 1, 12:50 AM EDTMonte Rosa Set To Report MRT-8102 Phase 1 Data In Cardiovascular Risk Study Today; Stock Up(RTTNews) – Monte Rosa Therapeutics (GLUE) said it will present clinical results today, October 1, 2026 from the GFORCE-1 Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk.
- RTTNews · Aug 24, 7:27 AM EDTMonte Rosa Doses First Patient In Phase 2 Study Of MRT-2359 In Prostate Cancer; Stock Up(RTTNews) – Monte Rosa Therapeutics, Inc. (GLUE), a clinical-stage biotechnology company that developed molecular glue degrader (MGD)-based medicines, announced that the first patient has been dosed in the phase 2 MODeFIRe-1 trial evaluating MRT-2359 in combination with apalutami
- Zacks · Aug 6, 9:50 AM EDTMonte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue EstimatesMonte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · Jun 29, 6:50 PM EDTAfter a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?The chief medical officer of Monte Rosa Therapeutics reported selling 41,845 shares directly for a transaction value of approximately $882,000, based on a weighted average price of around $21.08 per share over June 23–24, 2026.
- Zacks · May 7, 11:15 AM EDTMonte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue EstimatesMonte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Monte Rosa Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.